Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study
Carolina de Meneses-Gaya, José Alexandre S. Crippa, Jaime E. C. Hallak, et al.
Brazilian Journal of Psychiatry (2020) Vol. 43, Iss. 5, pp. 467-476
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications
Ainhoa Bilbao, Rainer Spanagel
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 107
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
Jonathon C. Arnold, Danielle McCartney, Anastasia Suraev, et al.
Clinical and Translational Science (2022) Vol. 16, Iss. 1, pp. 10-30
Open Access | Times Cited: 54
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022)
José Diogo R. Souza, Júlia Cozar Pacheco, Giordano Novak Rossi, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2598-2598
Open Access | Times Cited: 38
The therapeutic potential of purified cannabidiol
Saoirse E. O′Sullivan, Sanne Jensen, Gitte Nykjaer Nikolajsen, et al.
Journal of Cannabis Research (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 29
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Inga Dammann, Cathrin Rohleder, F. Markus Leweke
Pharmacopsychiatry (2024) Vol. 57, Iss. 03, pp. 115-132
Closed Access | Times Cited: 13
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders
Olivier J. Manzoni, Antonia Manduca, Viviana Trezza
Trends in Pharmacological Sciences (2025)
Open Access | Times Cited: 1
Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo‐controlled trial
Violaine Mongeau‐Pérusse, Suzanne Brissette, Julie Bruneau, et al.
Addiction (2021) Vol. 116, Iss. 9, pp. 2431-2442
Open Access | Times Cited: 47
‘Resurgent’, ‘twin’ or ‘silent’ epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America
Benedikt Fischer, Caroline O’Keefe-Markman, Angelica Lee, et al.
Substance Abuse Treatment Prevention and Policy (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 44
Cannabidiol and substance use disorder: Dream or reality
Saeideh Karimi‐Haghighi, Yasaman Razavi, Daniela Iezzi, et al.
Neuropharmacology (2022) Vol. 207, pp. 108948-108948
Open Access | Times Cited: 33
Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review
Graziella Madeo, Ashita Kapoor, Raffaele Giorgetti, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 11, pp. 2323-2342
Open Access | Times Cited: 14
The differential effects of medicinal cannabis on mental health: A systematic review
Nora de Bode, Emese Kroon, Sharon R. Sznitman, et al.
Clinical Psychology Review (2025), pp. 102581-102581
Closed Access
Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance
Andrea J. Narayan, Luke A. Downey, Brooke Manning, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 143, pp. 104941-104941
Closed Access | Times Cited: 21
Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review
Dângela Layne Silva Lassi, André Malbergier, André Brooking Negrão, et al.
Brain Sciences (2022) Vol. 12, Iss. 11, pp. 1546-1546
Open Access | Times Cited: 18
Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial
Violaine Mongeau‐Pérusse, Élie Rizkallah, Florence Morissette, et al.
Journal of Addiction Medicine (2022) Vol. 16, Iss. 5, pp. 521-526
Closed Access | Times Cited: 14
THC, CBD, and Anxiety: a Review of Recent Findings on the Anxiolytic and Anxiogenic Effects of Cannabis’ Primary Cannabinoids
Sarah Lichenstein
Current Addiction Reports (2022) Vol. 9, Iss. 4, pp. 473-485
Open Access | Times Cited: 14
Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review
Lindsay A. Lo, Caroline A. MacCallum, Kate Nanson, et al.
The Canadian Journal of Psychiatry (2023) Vol. 68, Iss. 8, pp. 557-571
Open Access | Times Cited: 8
Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap
Grégoire Cleirec, Esther Desmier, Cristina Lacatus, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 13
Cannabidiol Compared to Pharmacological Treatment as Usual for Crack Use Disorder: A Feasibility, Preliminary Efficacy, Parallel, Double-Blind, Randomized Clinical Trial
Andréa Donatti Gallassi, André Wagner Carvalho de Oliveira, Larissa Alencar Rodrigues, et al.
International Journal of Mental Health and Addiction (2024)
Open Access | Times Cited: 2
Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets
Justin R. Yates
Substance Abuse and Rehabilitation (2024) Vol. Volume 15, pp. 125-161
Open Access | Times Cited: 2
The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials
Carly de Faria Coelho, Rodolfo P. Vieira, Osvaldo Soares Araújo-Junior, et al.
Life (2024) Vol. 14, Iss. 11, pp. 1373-1373
Open Access | Times Cited: 2
Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies
Dimitri Daldegan‐Bueno, Lucas Oliveira Maia, Michelle Glass, et al.
European Neuropsychopharmacology (2021) Vol. 51, pp. 106-131
Open Access | Times Cited: 13
Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies
Dimitri Daldegan‐Bueno, Lucas Oliveira Maia, Michelle Glass, et al.
Psychopharmacology (2021) Vol. 239, Iss. 5, pp. 1211-1230
Open Access | Times Cited: 13
Evidence from Human Studies for Utilising Cannabinoids for the Treatment of Substance-Use Disorders: A Scoping Review with a Systematic Approach
Kayvan Ali Gharbi, Yvonne Bonomo, Christine Mary Hallinan
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 5, pp. 4087-4087
Open Access | Times Cited: 5
Cannabidiol attenuates the expression of conditioned place aversion induced by naloxone-precipitated morphine withdrawal through the activation of 5-HT1A receptors
Adriana Jesus Souza, Francisco Silveira Guimarães, Felipe V. Gomes
Behavioural Brain Research (2023) Vol. 450, pp. 114504-114504
Closed Access | Times Cited: 5
Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?
João Ariel Bonar Fernandes, Renato Filev, Thiago Marques Fidalgo
Cannabis and Cannabinoid Research (2023) Vol. 8, Iss. 5, pp. 703-715
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top